Skip to main content


Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Fig. 1 | BMC Cancer

Fig. 1

From: FRAX597, a PAK1 inhibitor, synergistically reduces pancreatic cancer growth when combined with gemcitabine

Fig. 1

PAK1 is up-regulated in pancreatic cancer specimens and pancreatic cancer cell lines. (a) Acinar and ductal cells in normal pancreas are not stained for PAK1 by immunohistochemistry (IHC), but islet cells (arrow) are positive. Magnification: x200. Pancreatic ductal adenocarcinomas stain more strongly for PAK1 than the negative control (CT). Magnification: x100. (b) The normal pancreas cell line, HPDE, expressed low levels of phospho-PAK1 (active form) and PAK1 as detected by western blotting. All pancreatic cancer cell lines, MiaPaCa-2, PANC-1, BxPC-3, Pan02 and LM-P expressed phospho-PAK1 and PAK1. The data represent mean ± SEM, summarised from three independent experiments. * p < 0.05; ** p < 0.01, compared to all other pancreatic cancer cell lines

Back to article page